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Edited by Daniela RuﬀellAbstract Spatial and temporal control of ovine prion protein
(Prnp) gene expression was achieved in mice using two trans-
genes: a Prnp minigene with tet-operator sequences inserted 5 0
to exon 1 and a mouse neuroﬁlament genomic clone carrying
the chimeric-repressor TRSID cDNA. In bi-transgenic mice,
ovine PrPC expression could be reversibly controlled in neuronal
cells by doxycycline treatment whereas it remains constant in
other cell types. Overall, this model opens opportunities to assess
the involvement of cell types in prion diseases and PrP physiolog-
ical function. It demonstrates the potentiality of the TRSID-
silencer to precisely control temporal and spatial gene expression
in vivo.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Gene regulation1. Introduction
Transmissible spongiform encephalopathies (TSE) are fatal
neurodegenerative disorders of animals and humans caused
by prions, a class of unconventional infectious agents that tar-
get predominantly the central nervous system [1,2]. Prion rep-
lication is associated with the conversion of the host encoded
cellular prion glycoprotein (PrPC) to an abnormally folded iso-
form (PrPSc), thus conferring partial resistance to proteolytic
degradation and insolubility in the presence of detergents.
PrPSc accumulation in the brain of diseased individuals is the
only known speciﬁc hallmark of TSE (reviewed in [1,3,4]).
The central role of PrPC in the susceptibility to disease was
clearly established with the demonstration that transgenic mice
in which the PrP gene (Prnp) has been invalidated were refrac-
tory to experimental infection with TSE agents [5–8]. Further-Abbreviations: TSE, transmissible spongiform encephalopathies; tTA,
tetracycline trans-activator; TRSID, chimeric tetracycline repressor
that recruits histone deacetylases; PrPC, cellular prion protein; PrPSc,
scrapie-associated PrP
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doi:10.1016/j.febslet.2008.05.014more, the lack of PrPC did not apparently dramatically aﬀect
the development or the behaviour of these mice [9,10].
More recently, post-natal depletion of neuronal PrPC in
transgenic mice was shown to have no eﬀect on neuronal sur-
vival [11], to prevent disease and to reverse spongiosis, early
cognitive deﬁcits and neurophysiological dysfunction upon
prion infection [12,13]. Similarly, targeted expression or deple-
tion of Prnp expression in several cell types has allowed to de-
ﬁne their involvement in the propagation of the infectious
agent and/or their relationship with its cellular toxicity ([14]
for review). In all these experiments, the depletion or expres-
sion of PrPC is irreversible. Only a few attempts to control
both the spatial and temporal expression pattern of this gene
have been reported. In bi-transgenic mice into which the trans-
activator, tTA was under the transcriptional regulation of the
Prnp promoter, expression of PrPC was reversibly regulated by
doxycycline [15]. It allowed the demonstration of the modula-
tion of prion disease by PrPC expression [15] and an assess-
ment of prion clearance in vivo [16].
In the present study, we assessed the possibility to tempo-
rally and spatially control in vivo the Prnp gene expression
leaving its expression pattern unchanged in untargeted tissues.
To this aim, we applied a strategy primarily validated in vitro,
which is based both on the use of a novel chimeric repressor
that recruits histone deacetylases (TRSID) and on the addition
of tet-operator sequences 5 0 to the ﬁrst exon of the gene of
interest [17]. Our results demonstrate the feasibility of this ap-
proach in vivo with a speciﬁc modulation of the Prnp gene
expression in the neurons of transgenic mice by doxycycline.
2. Materials and methods
2.1. Construction of the transgenes
2.1.1. Construction of the modiﬁed Tg1-ovine PrPVRQ-expressing
TgPrP vector. This vector is based on the previously described Tg1
plasmid [18]. The proximal mouse Prnp promoter was PCR-ampliﬁed
from the Tg1 plasmid using the primers 5 0-TTACTGCAGTCCGG-
AGCGGTGAC-3 0 and 5 0-CGCGGTCGACCGGGGAGTGGAAA-
3 0, digested by PstI and SalI and subcloned into the corresponding
sites of pPolyIII-I [19], leading to the pPrnp50 vector. The heptomer-
ized upstream tet-operators were PCR-ampliﬁed from the pUHD10-
3 vector, a kind gift of Prof. H. Bujard (University of Heideilberg, Hei-
delberg, Germany) using the primers 5 0-TCTATCTCGAGAGAGC-
TCTCCC-30 and 5 0-TGGTCTAGAAAACAGCGTGGATGG-3 0, di-
gested by XhoI and XbaI and subcloned into the SalI/XbaI-digestedblished by Elsevier B.V. All rights reserved.
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passing exon 1 to exon 2 of the Tg1 Prnp-minigene was ampliﬁed by
PCR using the primers 5 0-CTCTCTAGACCCCCGCGTTG-3 0 and
5 0-CCTGCCCGGGATACCGGCTTCC-3 0, digested by XbaI and
SmaI and cloned into the XbaI/SmaI digested pPrnpTetO5 0 vector. Fi-
nally, the BspeI/SmaI insert of this plasmid was isolated and cloned in
place of the corresponding fragment of the Tg1 Prnp minigene, leading
to the TgPrP plasmid. The TgPrP transgene (Fig. 1A) was released by
SalI/NotI digestion and gel puriﬁed.
2.1.2. Construction of the TgTRSID plasmid, a neuronal-targeted
TRSID expressing vector. The TRSID cDNA was realised from the
pTHE plasmid [17] by digestion with XbaI/BamHI, and subcloned into
a XbaI/BamHI digested pPolyIII-I plasmid. The BamHI/HindIII
SV40-polyadenylation sequence was released from the pUHD10-3
plasmid and subcloned 3 0 of the TRSID cDNA using the same restric-
tion sites of pPolyIII-I. The NotI TRSID-SV40-polyA insert was sub-
cloned into the NotI site of the neuroﬁlament NFH genomic clone
exon I sequence [20], orientated by restriction mapping, leading to
the TgTRSID plasmid. The TgTRSID transgene (Fig. 1B) was released
by KpnI/SalI digestion and gel puriﬁed.
2.1.3. Generation and analyses of transgenic mice. The TgPrP and
TgTRSID constructs were injected into FVB/N Prnp knockout mouse
eggs. Transgenic mice were identiﬁed by PCR analysis of their tail
genomic DNA using the set of primers 5 0-AACCGCTATCCACCT-
CAGGG-30, 5 0-AAAGAGGATCACACTTGC-3 0 and 5 0-TAT-
GCACTCAGCGCTGTGGG-3 0, 5 0-CACTGCATTCTAGTTGTGG-
3 0 for TgPrP and TgTRSID mice, respectively.
Analysis of the ovine Prnp gene expression in TgPrP and TgTR-
SID · TgPrP mice was performed as already described [18]. To detect
PrPC in the brain, histoblots were prepared as described [21]. PrPC was
detected with 12F10 antibody [22]. Assessment of ovine PrPC levels
was performed either indirectly by Elisa analysis of blood serum pro-
teins, using 11C6 anti-PrP antibody for the capture and acetylcholines-
terase-conjugated Bar224 anti-PrP antibody as a tracer (S. Simon,
CEA, France, unpublished results) or by detection of brain PrPC by
western blot using 4F2 antibody [22]. Brieﬂy 20% brain homogenate
were mixed volume to volume with Laemmli buﬀer before denatur-
ation at 100 C for 5 min and centrifugation at 15000 · g for
15 min. For each mouse analysed, an equal volume of supernatant
was loaded on 12% tris-tricine gels (Invitrogen).
Expression of the TgTRSID transgene was detected by RT-PCR
analysis of total brain RNA samples using the SuperScript synthesis
system (Invitrogen) and the set of primers mentioned above for tail
analysis. As a control, expression of HPRT was analysed using prim-
ers: 5 0-GCAGTACAGCCCCAAAATGG-3 0 and 5 0-CAAACTTGTC-
TGGAATTTCAAATCC-3 0.
Quantitative gene expression analysis was performed on ABI
PRISM 7000 Sequence Detection System (Applied Biosystems) using
SYBR Green. 5 0-AATTACCCGACACCTGGCAAT-30 and 5 0-Fig. 1. Schematic representation of the transgenes. (A) TgPrP transgene: th
exon I. The grey boxes represent mouse exonic sequences, the black box, th
represent ﬂanking and intronic sequences. E: mouse NFH exons. The grey b
SV40-polyA sequences.CCTTGGGCCTTTCACAGGTC-3 0 primers were used for the house-
keeping gene, Cpr2 (GeneBank accession number: AL603787.8). The
cycling condition comprised 10 min at 95 C followed by 40 cycles at
95 C for 15 s and 60 C for 1 min. Each sample was analyzed in trip-
licate and data were analyzed with the 2DDCt methods [23].
TgPrP mice were inoculated intracerebrally with 20 ll of a 10% (w/v)
brain homogenate of the 127 S sheep scrapie strain propagated on
tg338 mice, as previously described [18,24]. Mice showing neurological
signs were monitored daily and killed in extremis. Brains were analyzed
for the presence of protease-resistant PrPSc (PrPres), as previously de-
scribed [18] using a biotinylated anti-PrP antibody Sha31 kindly pro-
vided by S. Simon and J. Grassi (CEA, France, [25]).
Doxycycline (Sigma) treatment was performed by adding doxycy-
cline to the drinking water of the mice at a ﬁnal concentration of
1 mg/ml (0.005% ethanol).
All mouse manipulations were done following the French Commis-
sion de Ge´nie Ge´ne´tique recommendations.3. Results and discussion
3.1. Generation and analysis of the TgPrP transgenic mouse
lines
The TgPrP transgene, an ovine PrPVRQ Tg1 transgene [18]
with tet-operator sequences inserted 5 0 of exon 1 (Fig. 1A),
was microinjected into FVB/N Prnp knockout eggs. Seven
transgenic founders were identiﬁed and all of them transmitted
the transgene to their progeny. Brain transgene expression was
assessed in adult F1 oﬀspring by Northern blot analysis. Only
two of the seven lines analysed, lines TgPrP.13 and TgPrP.21,
were found to express the transgene, both at physiological lev-
els (1–2·, Fig. 2A and data not shown). This percentage of
expressing lines is comparable with that observed in previous
experiments based on the phgPrP-vector [18,26]. The tissue-
distribution of ovine PrP in these two lines was further ana-
lysed by Northern and qPCR analyses of RNA samples from
various tissues, brain, spleen, liver, and kidney. It was found to
be similar for both lines and identical to that previously ob-
served with phgPrP vectors (Fig. 2B and data not shown).
Overall, these data suggest that insertion of tet-operator se-
quences close to the transcription start site does not substan-
tially aﬀect the gene expression proﬁle.
Five TgPrP.21 transgenic mice were intracerebrally inocu-
lated with the 127S sheep scrapie strain propagated on tg338e thin lines represent ﬂanking and intronic sequences. E1: mouse Prnp
e ovine PrPVRQ cDNA ORF. (B) TgTRSID transgene: the thin lines
oxes represent mouse exonic sequences, the black box, the TRSID and
Fig. 2. Transgenes expression analyses. (A) Northern blot analysis of TgPrP transgene expression. Northern blot was performed on total brain RNA
samples and hybridised with a Prnp cDNA probe that cross-hybridized with murine sequences. Top lane: origin of the samples. C: control FVB/N
Prnp knockout mouse. Detected mRNA are indicated on the right margin. Bottom ﬁgure: coommassie blue staining of the membrane. (B) Ovine
Prnp tissue-distribution in TgPrP.13 mice. All quantitative RT-PCR experiments were performed in at least two diﬀerent TgPrP.13 individuals.
Relative brain Prnp mRNA expression levels were arbitrary given the value of 1. CPR2 transcripts were used as internal controls. The liver result is
not given as no expression was detected, as expected. (C) TgTRSID expression analysis by RT-PCR. 1 kb: 1 kb DNA ladder, TgTRSID: number of
the TgTRSID transgenic line analysed. +: RT-PCR with reverse transcriptase. : RT-PCR lacking reverse transcriptase. Left margin: analysed
mRNA. The size of the ampliﬁed fragment is indicated on the right margin. (D) Detection of PrPres in the brain of terminally-ill scrapie-inoculated
TgPrP mice. Protease treatment and Western blot analysis were performed as previously described [18]. The equivalent of 1 mg of brain tissue was
loaded on 12% tris-tricine gels (Invitrogen). As control, 0.2 mg of brain tissue from terminally-ill tg338 mice [24], inoculated with the same scrapie
strain was treated in parallel.
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animals developed a typical neurological disease, with a mean
incubation time of 140 ± 4 days. The length of the clinical
phase was 10 days. The clinical symptoms were dominated
by lethargy, a waddling gait, a straight tail and a hunched pos-
ture. Mice were killed once loss of righting reﬂex was irrevers-
ible. All analysed brains accumulated detectable amounts of
PrPres by western blot (Fig. 2D). The incubation time observed
stands within the range expected for this strain used in trans-
genic mice expressing ovine PrPVRQ at physiological levels
[18], again suggesting that addition of the tet sequences did
not aﬀect signiﬁcantly the TgPrP transgene expression pattern.
Moreover, the PrPres electrophoretic proﬁle was found to be
identical (Fig. 2D and [18]).
3.2. Generation and analysis of TgTRSID transgenic mouse lines
The TgTRSID transgene (Fig. 1B) was microinjected into
FVB/N Prnp knockout eggs. Of the nine transgenic lines estab-
lished, none were shown to express the transgene by Northern
blot analysis of their total brain RNA (data not shown). How-
ever, RT-PCR experiments allowed us to detect its brain
expression in two of these lines, TgTRSID.39 and TgTR-
SID.41 (Fig. 2C). No expression was detected in other ana-
lysed tissues (data not shown).3.3. Generation and analysis of double transgenic mice
To assess the potential control of the ovine Prnp gene
expression by TRSID in neuronal cells, double transgenic mice
were created by crossing TgPrP.13 or TgPrP.21 mice with
TgTRSID.41 or TgTRSID.39 mice. Without doxycycline,
TRSID should inhibit the TgPrP transgene expression by
interacting with the tet-operator sequences. Addition of doxy-
cycline in the drinking water should induce the linking of
doxycycline to TRSID and avoid its binding to the TgPrP pro-
moter, resulting in the normal expression of this gene. In the
absence of doxycycline, no ovine PrPC could be detected in
the brain of double transgenic mice whereas mice that were gi-
ven doxycycline in their drinking water for at least three days
expressed PrPC at levels that compared with those observed in
TgPrP mice (Fig. 3A). All double transgenic mice (n = 10)
resulting from TgPrP · TgTRSID.39 crosses behave like this.
However it was noticed by protein blood ELISA or Western
blot analysis of brain samples that in the absence of doxycy-
cline, brain PrPC was expressed at levels similar to that of
TgPrP mice in 40% of the double TgPrP · TgTRSID.41 trans-
genic mice obtained. This absence of TRSID-induced TgPrP
gene silencing was associated with the lack of TgTRSID
expression (data not shown). No correlation could be made be-
tween this phenomenon and the sex of the used TgTRSID.41
Fig. 3. Ovine PrP expression analyses in double transgenic mice. (A) Representative western blot analysis of ovine PrPC regulation by doxycycline in
the brains of double TgTRSID.41/TgPrP.21 transgenic mice. Top lane: origin of the mice. PrP0/0: control FVB/N Prnp knockout mouse. +dox:
Animal having received doxycycline for 3 days. dox: animal without doxycycline. The immuno-globulin detected band (around 20 kda) in each
samples ensures that similar amounts of proteins were loaded. (B) Representative Western blot showing reversible TgTRSID transcriptional
regulation by doxycycline in double TgTRSID.41/TgPrP.21 transgenic miceTop lane: 1: Mouse with no doxycycline for 4 days. 2: Mouse with no
doxycycline for 4 days and then with doxycycline for 8 days. 3: Mouse with the same treatment as in 2 followed by 4 days without doxycycline. The
immuno-globulin detected band (around 20 kda) in each samples ensures that similar amounts of proteins were loaded. (C) Spatial regulation by
doxycycline of ovine PrP expression. All quantitative RT-PCR experiments were performed in at least two diﬀerent TgTRSID.TgPrP individuals.
Relative brain PrPC expression level of mice with doxycycline was arbitrary given the value of 1. CPR2 transcripts were used as internal controls.
Fig. 4. Histoblot analysis of regulation of PrPC regional distribution in double TgTRSID.41/TgPrP.21 transgenic mouse brains. Origin of the double
transgenic mice and status of the animals in relation to doxycycline treatment are given in the right margin.
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mechanism. It rather suggests a variegated expression of the
TgTRSID transgene in the TgTRSID.41 line [27–29]. Overall,
these data demonstrate that low levels of trans-repressor may
be enough to ensure a knockout-like phenotype.
We next assessed the modulation during mouse lifespan of
the TRSID-induced control of TgPrP transcription. To this
aim, a group of six animals were not given doxycycline for 4
days, then received the antibiotic for 8 days and again return
to a doxycycline-free diet for 4 days. After each treatment,
two mice were killed to detect by immunoblot the expression
of ovine PrPC in their brains. As illustrated in Fig. 3B, a tem-
poral, doxycycline-related, regulation of the TgPrP transgene
expression was observed in these TgTRSID · TgPrP mice. It
demonstrates that the histone deacetylation of the TgPrP pro-
moter induced by TRSID binding could be reversed. However,
doxycycline treatments shorter than 2 days were unable to re-
store the transgene expression (data not shown), suggesting
that this process needs a minimum of time to be achieved. This
observation contrasts with previously reported data that used
classical tetracycline-inducible systems for which the reversibil-
ity of the controlled transgene expression could be seen 24 h
after administration of the antibiotic [30]. Although we cannot
formally exclude that TRSID repress the TgPrP expression
through a sterical hindrance repression mode, it would rather
suggest that this regulation involves, as expected, the recruit-
ment of histone deacetylases. It is more and more suggested
that chromatin remodelling has a critical role in gene regula-
tion in non-dividing cells such as neurons, implying a dynamic
process in the absence of DNA replication ([31] for review).
Finally, histoblot analysis performed on brain sections of dou-
ble transgenic mice revealed that the observed repression of
TgPrP expression in the absence of doxycycline was uniform
(Fig. 4).
TRSID expression should be restricted to neuronal cells by
the use of the NFH-based transgene. Thus, the TgPrP tran-
scriptional regulation in non-neuronal tissues of double trans-
genic mice should not be aﬀected by doxycycline. Quantitative
RT-PCR analysis of the TgPrP-derived mRNA in the kidney
of TgTRSID · TgPrP mice receiving or not the antibiotic
was indeed found to be the same (Fig. 3C).
Overall, our results demonstrate the feasibility of the TRSID
approach in vivo to temporally and spatially control transgene
expression in speciﬁc cell populations. The two TgPrP trans-
genic lines obtained open new opportunities to modulate Prnp
gene expression in vivo to tackle questions on the involvement
of cell types on various aspects of prion diseases [12,13] and on
PrP physiological function. Furthermore, similar spatial and
temporal control of gene expression could be, in principle, ap-
plied to any other gene of interest. It would thus be useful to
consider the creation and characterization of various
TRSID-expressing mouse lines with respect to their patterns
of expression that could be used in combination with other
lines having speciﬁc modiﬁed transgenes carrying tet operator
sequences 5 0 to their ﬁrst exon. It remains however to be as-
sessed if this reversible control of gene expression can be ap-
plied during early embryogenesis [32].
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